Corporate Profile
HCW Biologics is a clinical-stage company advancing the development of transformative immunotherapies to lengthen healthspan by disrupting inflammaging.
HCW Biologics is a clinical-stage company advancing the development of novel immunotherapeutics designed to disrupt the link between chronic, low-grade inflammation and age-related disorders. This field, known as inflammaging, targets the unresolved inflammatory responses and chronic, low-grade inflammation associated with advancing age and believed to be a significant contributing factor to cancer and several chronic conditions, including cardiovascular disease, diabetes, neurodegenerative disease, and autoimmune disease.
HCW Biologics Inc.(NasdaqGM:HCWB) added to S&P TMI Index
Data Provided by Refinitiv. Minimum 15 minutes delayed.
| Filing date | Description | Form |
|---|---|---|
| D | ||
Additional proxy soliciting materials - definitive |
DEFA14A | |
Amended Registration statement for face-amount certificate companies |
S-1/A | |
Amended Registration statement for face-amount certificate companies |
S-1/A | |
Amended Registration statement for face-amount certificate companies |
S-1/A | |
Amendment to a previously filed 10-Q |
10-Q/A | |
Amendment to a previously filed 4 |
4/A |